Primary Immune Deficiency (PID) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Primary Immune Deficiency (PID) – Pipeline Review, H1 2017’, provides an overview of the Primary Immune Deficiency (PID) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID)

The report reviews pipeline therapeutics for Primary Immune Deficiency (PID) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Primary Immune Deficiency (PID) therapeutics and enlists all their major and minor projects

The report assesses Primary Immune Deficiency (PID) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Primary Immune Deficiency (PID)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ADMA Biologics Inc

Biotest AG

Genethon SA

GigaGen Inc

GlaxoSmithKline Plc

Green Cross Corp

Novartis AG

Octapharma AG

ProMetic Life Sciences Inc

Sangamo Therapeutics Inc

Shire Plc

Taiga Biotechnologies Inc

UCB SA

X4 Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Primary Immune Deficiency (PID) - Overview

Primary Immune Deficiency (PID) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Primary Immune Deficiency (PID) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development

ADMA Biologics Inc

Biotest AG

Genethon SA

GigaGen Inc

GlaxoSmithKline Plc

Green Cross Corp

Novartis AG

Octapharma AG

ProMetic Life Sciences Inc

Sangamo Therapeutics Inc

Shire Plc

Taiga Biotechnologies Inc

UCB SA

X4 Pharmaceuticals Inc

Primary Immune Deficiency (PID) - Drug Profiles

Antibody for Primary Immune Deficiency Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-595 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for RAG-Deficient Severe Combined Immune Deficiency - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for X-Linked SCID - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2696273 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) next generation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RI-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seletalisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for ADA Deficiency Related SCID - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Hematological Disorders and Primary Immune Deficiency - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Leukocyte Adhesion Deficiency - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Severe Combined Immunodeficiency - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate Artemis for SCID - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBX-1400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-4P001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Immune Deficiency (PID) - Dormant Projects

Primary Immune Deficiency (PID) - Product Development Milestones

Featured News & Press Releases

Nov 29, 2016: Option Care Has Been Selected as a National Provider of CUVITRU

Nov 23, 2016: Green Cross Receives Complete Response Letter from US FDA for IVIG-SN

Nov 16, 2016: Shire Launches CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency

Nov 12, 2016: Tolerability Data for Shires Cuvitru Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting

Sep 23, 2016: Shire To Showcase Data On Cuvitru During European Society For Immunodeficiencies Biennial Meeting

Sep 14, 2016: Shire Announces U.S. FDA Approval of CUVITRU Treatment for Primary Immunodeficiency

Aug 09, 2016: ProMetic Completes Adult Patients Enrolment in Pivotal IVIG Phase 3 Clinical Trial

Jun 10, 2016: Shire announces completion of decentralized procedure in Europe for Immunoglobulin Treatment Cuvitru

Mar 07, 2016: Green Cross Biotherapeutics Receives Health Canada Approval for Phase III Clinical Trials of IVIG 10%

Mar 03, 2016: Baxalta to Showcase Innovation Leadership in Primary Immune Deficiencies During 2016 American Academy of Allergy, Asthma & Immunology Annual Meeting

Jan 25, 2016: US FDA Accepts Green Cross' Biologics License Application for IVIG-SN

Dec 02, 2015: Baxalta Receives CHMP Positive Opinion on GAMMAGARD

Nov 24, 2015: Green Cross Submits Biologics License Application to US FDA for IVIG-SN

Oct 26, 2015: Prometic’s IVIG IND Cleared By FDA

May 21, 2015: Baxter BioScience Files for European Approval of Investigational 20% Subcutaneous Immune Globulin Treatment for Primary Immunodeficiency

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Primary Immune Deficiency (PID), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Primary Immune Deficiency (PID) – Pipeline by ADMA Biologics Inc, H1 2017

Primary Immune Deficiency (PID) – Pipeline by Biotest AG, H1 2017

Primary Immune Deficiency (PID) – Pipeline by Genethon SA, H1 2017

Primary Immune Deficiency (PID) – Pipeline by GigaGen Inc, H1 2017

Primary Immune Deficiency (PID) – Pipeline by GlaxoSmithKline Plc, H1 2017

Primary Immune Deficiency (PID) – Pipeline by Green Cross Corp, H1 2017

Primary Immune Deficiency (PID) – Pipeline by Novartis AG, H1 2017

Primary Immune Deficiency (PID) – Pipeline by Octapharma AG, H1 2017

Primary Immune Deficiency (PID) – Pipeline by ProMetic Life Sciences Inc, H1 2017

Primary Immune Deficiency (PID) – Pipeline by Sangamo Therapeutics Inc, H1 2017

Primary Immune Deficiency (PID) – Pipeline by Shire Plc, H1 2017

Primary Immune Deficiency (PID) – Pipeline by Taiga Biotechnologies Inc, H1 2017

Primary Immune Deficiency (PID) – Pipeline by UCB SA, H1 2017

Primary Immune Deficiency (PID) – Pipeline by X4 Pharmaceuticals Inc, H1 2017

Primary Immune Deficiency (PID) – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Primary Immune Deficiency (PID), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports